Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Jacques Kiladjian

Showing results (1-10 of 209) with videos related to

Pageof 21
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasmsJean-Jacques Kiladjian
La Revue Du Praticien|December 13, 2005
[Diagnosis and treatment of primary thrombocythemia]Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 13, 2012
The spectrum of JAK2-positive myeloproliferative neoplasmsJean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 7, 2024
Pegylated interferon: the who, why, and howJean-Jacques Kiladjian
Therapie|December 13, 2021
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematologyLina Benajiba, Jean-Jacques Kiladjian
Bulletin Du Cancer|August 7, 2016
[Not Available]Juliette Soret, Jean-Jacques Kiladjian
American Journal of Hematology|March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategiesJean-Jacques Kiladjian, Bruno Cassinat
Leukemia|July 11, 2020
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosisMoshe Talpaz, Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is there a role for the use of IFN-α in primary myelofibrosis?Huong Marie Nguyen, Jean-Jacques Kiladjian
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Ruxolitinib: a targeted treatment option for patients with polycythemia veraKris Vaddi, Srdan Verstovsek, Jean-Jacques Kiladjian
Pageof 21

Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasmsJean-Jacques Kiladjian
La Revue Du Praticien|December 13, 2005
[Diagnosis and treatment of primary thrombocythemia]Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 13, 2012
The spectrum of JAK2-positive myeloproliferative neoplasmsJean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 7, 2024
Pegylated interferon: the who, why, and howJean-Jacques Kiladjian
Therapie|December 13, 2021
The challenge of targets and drug discovery using large-scale screening approaches in onco-hematologyLina Benajiba, Jean-Jacques Kiladjian
Bulletin Du Cancer|August 7, 2016
[Not Available]Juliette Soret, Jean-Jacques Kiladjian
American Journal of Hematology|March 4, 2023
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategiesJean-Jacques Kiladjian, Bruno Cassinat
Leukemia|July 11, 2020
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosisMoshe Talpaz, Jean-Jacques Kiladjian
Hematology. American Society of Hematology. Education Program|December 13, 2012
Is there a role for the use of IFN-α in primary myelofibrosis?Huong Marie Nguyen, Jean-Jacques Kiladjian
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Ruxolitinib: a targeted treatment option for patients with polycythemia veraKris Vaddi, Srdan Verstovsek, Jean-Jacques Kiladjian
Pageof 21